Insufficient financing
The company expects continued losses and says it will require substantial additional capital to continue programs.
- Scope
- Could force delays, reductions or termination of development activities
- Materiality
- high
HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing immunotherapies and vaccine candidates built on its proprietary replicating and non-replicating viral vector technologies. The company has not commercialized any products and currently generates revenue only from collaboration and licensing agreements, primarily with Gilead and Roche.
−110,8 %
−99,0 %
+118,3 %
3.27
3.27
| % | |
|---|---|
| Vaccine and immunotherapy candidates | 0% Preclinical and clinical product candidates designed to prevent or treat serious diseases using viral-vector-based immunology. |
| Technology platforms | 0% Replicating and non-replicating viral vector technologies used to create new product candidates and partnership opportunities. |
| Collaboration and licensing revenue | 100% Upfront, milestone, initiation and reimbursement revenue from partner agreements such as Gilead and Roche. |
HOOKIPA does not sell commercial products today; its customers are collaboration partners that fund research and...
- Pharmaceutical collaboration partnersprimary
Large biopharma companies that pay upfront, milestone and reimbursement amounts to access HOOKIPA’s technology and programs.
- Government and grant funding sourcessecondary
Public-sector programs that provide research incentives and non-dilutive funding to support development work.
- Future patients and healthcare providersemerging
Patients and clinicians in HBV, HIV, oncology and other serious-disease areas that would use approved products if development succeeds.
HOOKIPA is headquartered in the United States but has meaningful operational exposure to Austria, where it references...
- •United States is the corporate base and key capital market exposure
- •Austria is important for operations and government research incentives
- •Global supply chain dependence creates cross-border manufacturing risk
- •Third-party suppliers are located outside the United States
- •Trade restrictions can affect research materials and clinical supply
The company’s near-term strategy is to advance current and future product candidates through preclinical and clinical...
01
Advance clinical and preclinical programsshort-term
Pipeline progress is the main value driver because the company has no product sales today.
02
Secure non-dilutive and dilutive fundingshort-term
The company expects continued losses and needs capital to avoid slowing or stopping development.
03
Strengthen manufacturing and commercialization readinessmedium-term
Approved products would require reliable supply, quality control and a sales infrastructure.
HOOKIPA faces classic clinical-stage biotech risks: program failure, delayed trials, regulatory setbacks and the need...
Clinical and regulatory failure
Product candidates must succeed in preclinical studies, clinical trials and regulatory review before any product revenue can begin.
- Scope
- Pipeline value and future commercialization depend on trial outcomes
- Materiality
- high
Third-party manufacturing dependence
HOOKIPA does not own or operate manufacturing facilities and relies on external suppliers and manufacturers.
- Scope
- Supply interruptions, quality issues and scale-up delays
- Materiality
- high
Collaboration concentration
Current revenue is concentrated in a small number of collaboration agreements, so termination or non-renewal would materially reduce revenue.
- Scope
- Gilead and Roche collaboration revenue
- Materiality
- high
Trade policy and tariff exposure
The company relies on a global supply chain and notes that tariffs and trade barriers could increase costs and delay development.
- Scope
- Suppliers outside the United States and imported research materials
- Materiality
- medium
Collaboration revenue recognition
Can create large quarter-to-quarter swings in revenue and earnings
Deferred revenue
Material effect on reported revenue and operating cash flow timing
Research incentives and receivables
Affects working capital and cash conversion
Estimates and judgments
Can affect asset, liability and expense recognition
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Vir Biotechnology, Inc.
VIR · Biological Products, (No Diagnostic Substances)
Cocrystal Pharma, Inc.
COCP · Pharmaceutical Preparations
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
: 28/04/2026